Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 223Carboplatin 219Cisplatin 206Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 115Pemetrexed 102Dexamethasone 102Cyclophosphamide 102Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 92Fluorouracil 88Bevacizumab 84Nivolumab 74Leucovorin 73Rituximab 71Vincristine 68durvalumab 66Lenalidomide 64Radiation 62Etoposide 62atezolizumab 61Irinotecan 61130-nm albumin-bound paclitaxel 58Prednisone 57Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × EC regimen × 1 year × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Shanghai Henlius Biotech

Phase 3 Active not recruiting
200 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡